# Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients

> **NCT02058602** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **OTHER:** Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months

## Key facts

- **NCT ID:** NCT02058602
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-03
- **Primary completion:** 2016-07-11
- **Final completion:** 2016-07-11
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02058602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02058602, "Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02058602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*